Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
Status:
Unknown status
Trial end date:
2018-12-30
Target enrollment:
Participant gender:
Summary
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA
receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute
ischemic stroke patients receiving endovascular treatment to remove clot within 8 hours
following stroke onset. Neu2000KWL will be administered before endovascular treatment.